CliffBio
biologic

Kovaltry

Antihemophilic Factor (Recombinant), Full Length

Loss of exclusivityMarch 2028projected — 12-year biologic exclusivity estimate
CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameKovaltry
Active ingredientAntihemophilic Factor (Recombinant), Full Length
Strength2000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2016
Marketing statusRx

More from Bayer Healthcare

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kovaltry patent cliff — loss of exclusivity March 2028 | CliffBio